Cubresa

Cubresa develops, markets and supports a brain imaging system for imaging clinics and hospitals. Imaging clinics are seeing increased demand for whole body applications such as prostate, which puts brain imaging applications on the backburner. A lower priced, brain optimized imaging system would be useful in this market because Alzheimer's imaging demand is starting to grow.  For these imaging clinics, we believe they will want a brain imaging system that can be used for existing applications, such as brain cancer and epilepsy surgical imaging, as well as for future Alzheimer's, Dementia or Parkinson's applications.   

Our BrainPET product is designed for this need. It retrofits into already installed MRI to provide MRI and molecular imaging at the same time. The system will work with most Siemens, GE, Philips and Canon MRI systems with light customization.  We believe BrainPET will be suitable for  brain cancer, epilepsy, and both Amyloid and Tau imaging for Alzheimer's.   We have 3 purchase orders in hand  from Barrow Neurological, Lawson Research and Massachusetts General. We have one installation at Lawson Research Institute in London, Ontario. Additional installation will occur in early 2024. We are working on multiple additional orders in 2024. 

These systems sell for $2M CDN and are expected to generate an additional $1M+ of service contracts over 10 years. Our marketplace allows 50% down payment with purchase order, 40% on shipment and 10% on acceptance.   

Cubresa is the only company in the world with a MR compatible BrainPET. We have several patents and patents pending that we have licensed into the company and are submitting additional patents as our development continues.  We believe this unique product makes us interesting to the large MRI companies.